METHOD FOR PNEUMOUSTIC PNEUMONIA PREVENTION IN HEART RECIPIENTS IN EARLY POSTOPERATIVE PERIOD AFTER HEART TRANSPLANTATION Russian patent published in 2017 - IPC A61B17/03 A61B5/145 A61B10/00 A61K31/63 A61P31/04 

FIELD: medicine.

SUBSTANCE: recipients are isolated who have been exposed to extracorporal membrane oxygenation technology for at least 24 hours and/or at least two of the following conditions have been identified: gram negative bacteremia after surgery, intraoperative blood loss of more than 500 ml, mechanical ventilation duration of more than 12 hours in the postoperative period. Such patients receive drug or drugs having a bactericidal or bacteriostatic activity against Pneumocystis jiroveci starting from 2-3 days after the operation, for 5-6 days intravenously at a therapeutic dose.

EFFECT: reduced toxic effect of multicomponent drug therapy as a result of a differentiated approach to administration of toxic and active agents against pneumocystis.

2 cl, 4 ex